Enliven Therapeutics
ELVN
31 hedge funds and large institutions have $26.2M invested in Enliven Therapeutics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 6 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
0.97% less ownership
Funds ownership: 14.22% → 13.25% (-0.97%)
11% less funds holding
Funds holding: 35 → 31 (-4)
22% less capital invested
Capital invested by funds: $33.6M → $26.2M (-$7.43M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $27K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPC
Lion Point Capital
New York
|
+$1.38M |
| 2 |
WP
Woodline Partners
San Francisco,
California
|
+$1.21M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$134K |
| 4 |
Bank of New York Mellon
New York
|
+$84.1K |
| 5 |
Two Sigma Advisers
New York
|
+$43.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.7M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$459K |
| 3 |
Morgan Stanley
New York
|
-$377K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$360K |
| 5 |
D.E. Shaw & Co
New York
|
-$189K |
ELVN Hedge Fund Activity: Q1 2022 in Review
31 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q1 2022, worth a combined $26.2M — down 22% from $33.6M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ELVN and 2 opened new positions — a net loss of 4 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was Lion Point Capital, opening a new position worth an estimated $1.38M. The largest seller was Fidelity Investments, cutting an estimated $2.7M.
- 31 institutional investors held Enliven Therapeutics (ELVN) as of Q1 2022, down from 35 in Q4 2021.
- Funds reported $26.2M of Enliven Therapeutics stock for Q1 2022, down 22% quarter-over-quarter.
- 2 funds opened new Enliven Therapeutics positions in Q1 2022 and 6 closed out, a net change of -4 holders.
- The largest Enliven Therapeutics buyer in Q1 2022 was Lion Point Capital, an estimated $1.38M added.
- The largest Enliven Therapeutics seller in Q1 2022 was Fidelity Investments, an estimated $2.7M sold.
Based on aggregated 13F filings for Q1 2022.